-
Je něco špatně v tomto záznamu ?
Nanoformulations for dermal delivery of imiquimod: The race of "soft" against "hard"
E. Petrová, S. Chvíla, M. Balouch, F. Štěpánek, J. Zbytovská
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- imichimod chemie MeSH
- kůže metabolismus MeSH
- lipidy farmakologie MeSH
- liposomy * farmakologie MeSH
- nanokapsle * MeSH
- Publikační typ
- časopisecké články MeSH
Imiquimod (IMQ) is an immunostimulating agent used in the treatment of basal cell carcinoma and actinic keratosis. Due to its low solubility and poor skin bioavailability, the dermal formulation of IMQ remains challenging. In analogy to tyre compounds used in Formula 1 racing, we compare four types of nanosystems belonging to three groups: (i) "hard" nanoparticles in the form of IMQ nanocrystals, (ii) "intermediate" nanoparticles in the form of liposomes and lipid nanocapsules, and (iii) "soft" nanoparticles in the form of a nanoemulsion based on oleic acid. The nanoemulsion and nanocrystals were able to incorporate the highest amount of IMQ (at least 2 wt%) compared to liposomes (0.03 wt%) and lipid nanocapsules (0.08 wt%). Regarding size, liposomes, and lipid nanocapsules were rather small (around 40 nm) whereas nanocrystals and nanoemulsion were larger (around 200 nm). All developed nanoformulations showed high efficiency to deliver IMQ into the skin tissue without undesirable subsequent permeation through the skin to acceptor. Especially, the 2 wt% IMQ nanoemulsion accumulated 129 μg/g IMQ in the skin, compared to 34 μg/g of a 5 wt% commercial cream. The effects of the respective nanoparticulate systems were discussed with respect to their possible diffusion kinetics (Brownian motion vs. settling) in the aqueous phase.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000228
- 003
- CZ-PrNML
- 005
- 20240213093026.0
- 007
- ta
- 008
- 240109e20231104ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijpharm.2023.123577 $2 doi
- 035 __
- $a (PubMed)37931726
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Petrová, Eliška $u Department of Organic Technology, University of Chemistry and Technology Prague, Technická 5, Prague, Czech Republic
- 245 10
- $a Nanoformulations for dermal delivery of imiquimod: The race of "soft" against "hard" / $c E. Petrová, S. Chvíla, M. Balouch, F. Štěpánek, J. Zbytovská
- 520 9_
- $a Imiquimod (IMQ) is an immunostimulating agent used in the treatment of basal cell carcinoma and actinic keratosis. Due to its low solubility and poor skin bioavailability, the dermal formulation of IMQ remains challenging. In analogy to tyre compounds used in Formula 1 racing, we compare four types of nanosystems belonging to three groups: (i) "hard" nanoparticles in the form of IMQ nanocrystals, (ii) "intermediate" nanoparticles in the form of liposomes and lipid nanocapsules, and (iii) "soft" nanoparticles in the form of a nanoemulsion based on oleic acid. The nanoemulsion and nanocrystals were able to incorporate the highest amount of IMQ (at least 2 wt%) compared to liposomes (0.03 wt%) and lipid nanocapsules (0.08 wt%). Regarding size, liposomes, and lipid nanocapsules were rather small (around 40 nm) whereas nanocrystals and nanoemulsion were larger (around 200 nm). All developed nanoformulations showed high efficiency to deliver IMQ into the skin tissue without undesirable subsequent permeation through the skin to acceptor. Especially, the 2 wt% IMQ nanoemulsion accumulated 129 μg/g IMQ in the skin, compared to 34 μg/g of a 5 wt% commercial cream. The effects of the respective nanoparticulate systems were discussed with respect to their possible diffusion kinetics (Brownian motion vs. settling) in the aqueous phase.
- 650 _2
- $a imichimod $x chemie $7 D000077271
- 650 12
- $a liposomy $x farmakologie $7 D008081
- 650 12
- $a nanokapsle $7 D053769
- 650 _2
- $a kůže $x metabolismus $7 D012867
- 650 _2
- $a lipidy $x farmakologie $7 D008055
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Chvíla, Stanislav $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Balouch, Martin $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Štěpánek, František $u Department of Chemical Engineering, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic
- 700 1_
- $a Zbytovská, Jarmila $u Department of Organic Technology, University of Chemistry and Technology Prague, Technická 5, Prague, Czech Republic. Electronic address: jarmila.zbytovska@vscht.cz
- 773 0_
- $w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 648 (20231104), s. 123577
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37931726 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093023 $b ABA008
- 999 __
- $a ok $b bmc $g 2049106 $s 1209922
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 648 $c - $d 123577 $e 20231104 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
- LZP __
- $a Pubmed-20240109